Can I join a MOTS-c clinical trial?

1 trial is recruiting or about to, with sites in China. Eligibility and contacts are on each trial's ClinicalTrials.gov page.

Home · Clinical trials

MOTS-c clinical trials

Q: Are there clinical trials of MOTS-c?

ClinicalTrials.gov lists 2 registered trials of MOTS-c: 1 recruiting or about to, 0 running, 1 completed. Recruiting sites are in China. The largest is MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (120 people).

ClinicalTrials.gov lists 2 registered trials of MOTS-c: 1 recruiting or about to, 0 running, 1 completed. Recruiting sites are in China. The largest is MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (120 people).

2registered trials

1recruiting now

0running

1completed

0in phase 3

0with results posted

Recruiting 1
Completed 1

MOTS-c research (grade C)MOTS-c prices Search ClinicalTrials.gov

Where MOTS-c is in testing

Registered trials by phase. Phase 3 trials are the large ones that decide approval.

0Early phase 1First doses in people

1Phase 1Safety and dosing

1Phase 2Does it work?

0Phase 3Large confirmatory trials

0Phase 4After approval

0Not phasedObservational and other

Timeline

Each bar runs from a trial's start to its planned end; faded bars have no end date. Click a bar to open the trial.

RecruitingRunningCompletedStopped or withdrawnStatus unknownToday

Where trials are recruiting

Countries with sites in trials that are recruiting now.

China1

Recruiting now 1

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

RecruitingPhase 2120 peopleRandomizedHudson Biotech2026-02-02 → 2027-02-14🇨🇳 China

Studying: Prediabetes, Insulin Resistance, Overweight/Obesity · NCT07505745

About this trial

This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.

Completed 1

A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease

CompletedPhase 188 peopleRandomizedCohBar, Inc.2018-07-09 → 2021-04-19🇺🇸 United States

Studying: Nonalcoholic Fatty Liver Disease · NCT03998514

About this trial

This is a 3 part, randomized, double blind, placebo controlled study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending subcutaneous (SC) doses of CB4211 in healthy non obese subjects and subjects with NAFLD.

Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (MOTS-c, CB4211) in the listed interventions.